Indivior Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Supernus

29/10/2026 20:09

Indivior Pharmaceuticals Inc INDV.OQ reported quarterly adjusted earnings of $1.32​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 72 cents.  The mean expectation of three analysts for the quarter was for earnings of $1.12 per share. Wall Street expected results to range from $1.09  to $1.15 per share.
Revenue rose 13.4% to $356.00 million from a year ago; analysts expected $329.35 million. 
Indivior Pharmaceuticals Inc's reported EPS for the quarter was $1.12​.
The company reported quarterly net income of $137 million.
Indivior Pharmaceuticals Inc shares had fallen by 3.0% this quarter and lost 3.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 21.5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Indivior Pharmaceuticals Inc is $50.00, about 30.5% above its last closing price of $34.77
This summary was machine generated from LSEG data October 29 at 08:09 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
1.12
1.32
Beat
Jun. 30 2026 
0.87
1.15
Beat
Mar. 31 2026 
0.66
0.96
Beat
Dec. 31 2025 
0.67
0.82
Beat